StemCell Therapy

Leber's Hereditary Optic Neuropathy (LHON) is a maternally inherited mitochondrial disease, characterized by acute or subacute, painless vision loss or even loss simultaneously or sequentially, accompanied by central visual field defect and color vision impairment with poor prognosis. It was first reported by German scholar Leber in 1871. It affects about 1-9:100,000 people worldwide. LHON is one of the blinding diseases. The disease mainly occurs in young- and middle-aged men. Currently, there is no effective treatment for LHON. About 70% - 90% of LHON is caused by ND4 mutation of harboring a point mutation at nucleotide 11778 associated with a G-to-A transition. With the development of NR082, AAV-based gene therapy of LHON becomes possible.

"Due to the lack of effective treatment, the quality of life of LHON patients associated with ND4 mutation is very poor, and a huge unmet medical needs have not been fulfilled," said Dr. Alvin Luk, Chief Executive Officer at Neurophth. "NR082 is the first candidate drug developed by Neurophth. It uses recombinant adeno-associated virus serotype 2 to deliver the genetically modified ND4 gene (rAAV2-ND4). After a single intravitreal injection, the gene is translated and expressed in cells, which effectively supplements the function loss caused by endogenous mutation. Through this gene therapy, the electron transport function of mitochondrial respiratory chain was maintained, and the increase of ATP synthesis restored the normal function of mitochondria, which in turn improved the sensory function of the retinal ganglion cells and improved the visual acuity of LHON patients."

Luk added, "the significance of orphan drug designation is that regulators recognize the unmet medical needs of rare diseases like LHON. The recognition of NR082 will reduce the R&D investment to a certain extent and accelerate the progress of clinical trials and marketing registration. Furthermore, Neurophth is committed to fundamentally solve the causes and change the quality of life of patients through a single treatment of gene therapy."

Professor Bin Li, Founder, Chairman and Chief Scientific Officer at Neurophth, said: "NR082 has been granted as orphan drug by U.S. FDA, which further strengthens our focus on gene therapy for rare ophthalmic diseases, and develops more drugs for treatment of ocular genetic diseases, bringing hope to patients with ocular genetic diseases in the world".

*FDA grants orphan drug designation to drugs and biological products designed to safely and effectively treat, diagnose, or prevent rare diseases or conditions affecting less than 200,000 people in the US. According to the Orphan Drug Act of FDA, Orphan Drug Designation (ODD) provides opportunities for grant funding, fast approval channel, and some incentives, such as waiver of New Drug Application (NDA) fees, tax credits for clinical trial expenses and exemption for prescription drug users' fees as well as the products are entitled to a seven-year of market exclusivity and will not be affected by patents.

About NR082 (rAAV2-ND4; NFS-01 Project)

LHON disease is caused by mutations in mitochondrial DNA 11778, 14484 or 3460. ND4 gene of 11778 G>A mutation is the main pathological factor, which exists in 55-70% of European and American patients and 90% of Chinese patients. NR082 (NFS-01 project) is an innovative candidate drug for ophthalmic AAV-based gene therapy. It uses AAV2 vector to express human ND4 gene in the retinal ganglion cells to repair optic neuropathy caused by 11778 G>A mutation.

As early as 2011, Professor Bin Li's team started the world's first LHON gene therapy investigator-initiated trial (IIT) with this candidate drug. Nine subjects who participated in the clinical trial have been followed up for up to 8 years with no serious adverse reactions, and 5 of them have significant improvement in their vision. This result is the longest follow-up record of gene therapy in the world, which has already been published in the Scientific Report, EBioMedicine and Ophthalmology journals, and has fully proven the long-term safety, effectiveness, and durability of AAV gene therapy in clinical settings.

After the gratifying results of the first study, Professor Li's team conducted a more comprehensive IIT clinical study from 2017 to 2018, with 159 subjects (including 10 subjects from Argentina), which is the largest clinical trial in the entire gene therapy in the world. Among those, 143 of the patients has completed the 12-month follow-up and 56.6% showed a significant BCVA (best-corrected visual acuity improved by at least 0.3 LogMAR) improvement. No serious adverse reaction was found. In May 2020, at the 23rd online annual meeting of the American Society for Gene and Cell Therapy (ASGCT) and the online annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), Neurophth presented these two clinical research data on the treatment of LHON with NR082 (NFS-01 project of rAAV2-ND4), demonstrating the international advanced level of this research in the field of gene therapy.

Following the positive results of these two IIT trials, Neurophth is actively preparing the China/U.S. IND (Investigational New Drug) applications, and plans to carry out the registration clinical Phase 1/2/3 registration trial to evaluate the safety, efficacy and durability of NR082.

About Neurophth

As a clinical-stage R & D company, Neurophth is committed to exploring and developing new therapies for global patients with ophthalmic diseases. With the help of the mature AAV ophthalmic gene therapy technology platform and the deep understanding of the ophthalmology field by the founding team for decades, Neurophth has established a rich, robust product pipeline, including more than 10 research projects for various ophthalmic diseases, such as dominant hereditary optic atrophy, optic nerve injury diseases, vascular retinopathy, etc., and gradually expanded from rare to common ophthalmic diseases. Additionally, the company is preparing to build a GMP commercial production platform for gene therapy drugs accordance with the international quality standards, and plans to build an ophthalmic gene therapy transformational excellence center, aiming to become a global leader in gene therapy in ophthalmology to benefit patients all over the world.

Prospect of Gene Therapy in Ophthalmology

Inherited retinal diseases (IRDs) have long been regarded as an ideal disease area for gene therapy, because most of the gene mutations leading to the disease have been identified (more than 200 gene defects are associated with the most common IRDS). The eye is, to some extent, an immune privilege. Clinical trials have shown that gene therapy using adeno-associated virus (AAV) or lentivirus (LV) vectors in the eye does not cause systemic side effects and does not cause significant immune responses. The most common IRDs were Retinitis Pigmentosa (RP), Achromatopsia color blindness (ACHM), Leber Hereditary Optic Neuropathy (LHON), Leber Congenital Amaurosis (LCA), Stargardt disease and X-linked Retinoschisis (XLRS).

To date, only one ophthalmic AAV gene therapy product has been approved in the world, namely the first AAV2 gene therapy voretigene neparvovec-rzyl (LUXTURNA; Spark Therapeutics) approved by FDA in December 2017 to treat IRD caused by RPE65 double allele mutation in adult or pediatric patients. The approval of LUXTURNAhas brought confidence and hope to the global ophthalmic gene therapy field. Public information disclosed that at least 20-30 kinds of gene therapy for ophthalmic diseases are in the research and development stage, and the international representative companies include Applied Genetic Technologies Corporation and Meira GTX, and new companies represented by Neurophth have also begun to enter the international stage of ophthalmic gene therapy.

References

Contact:Dr. Alvin Luk[emailprotected]

SOURCE Neurophth Therapeutics, Inc.

Read the original post:
Neurophth Therapeutics' Treatment of Leber's Hereditary Optic Neuropathy Gene Therapy NR082 was Granted Orphan Drug Designation by US FDA - PRNewswire

The Warriors are back in the lab and putting up shots in the Warriors Minicamp, presented by Oracle NetSuite. One of those ready to step back on the hardwood and get their reps in is center Kevon Looney. After a 2019-20 campaign in which he appeared in just 20 of the Dubs 65 games due to a combination of neuropathy and abdominal soreness, Looney says he is doing great and ready to test himself.

See what else the Dubs center had to say following Thursdays practice below:

On his recovery from abdominal surgery in May:I had a lot of time to take my time on the rehab and I didnt have to rush this as though we were playing, so I was able to be really detail-oriented about it and make sure I was feeling 100 percent before stepping on the court and before pushing myself this camp is great for me so I have a chance to play (with) these guys, really test myself and see where Im at.

On what helped him through his injuries during the 2019-20 season:Just being in a good atmosphere like the Warriors. Just having the support of the coaches, the training staff and players made a tough time easier. Kinda got down on myself: signed that contract and wanted to come in and have a big year, but things didnt go as planned. To get injured again, and then get injured again, was kinda frustrating I got a lot of trust in our training staff and that theyre going to put me in a position to succeed. I was able to lean on my family, lean on my teammates, lean on fans. I always have my support.

His feelings on current racial inequality and overcoming the obstacles:Its been a tough time seeing what happened to James Blake. Hes not the first, and probably wont be the last its sad to say. Growing up in Milwaukee, seemed like every couple of months or every couple of years something like this happens Gotta try to persevere, gotta try to stay hopeful, try to encourage people to do the right thing, try to get them to protest peacefully, get them to go out there and vote.

Continue reading here:
What They Are Saying in The Dubble - 9/24/20 - Warriors.com

Skyler Simpkins 23

Opinion Editor

When all other options fail, acupuncture is often recommended for those suffering unbearable neuropathy. My father, who was diagnosed with pancreatic cancer last year, developed severe neuropathic symptoms as a side effect of chemotherapy. His doctors recommended that he receive acupuncture after a plethora of other treatments showed no improvement. The appointment was made and my father was optimistic. A short time before the appointment, the therapist called him and cancelled his appointment due to suspicion of coronavirus infection. The only basis the therapist had for cancelling treatment was that my dad had recently traveled to Florida, a coronavirus hotspot. My father was denied life-altering treatment due to mere suspicion. It was at this moment that I saw the effect of coronavirus anxiety on the health of a loved one, and I quickly realized an egregious problem in our modern, pandemic-defined society.

In the age of coronavirus, we have seen the reemergence of infectious disease discrimination. While this discrimination has always existed, it is now more prevalent and apparent than ever. This can be experienced on a daily basis when wefor examplevisit a store or take public transportation. I would believe that most of us would agree with this, as do I, because these are private businesses enforcing their own jurisdiction over their property. Also, many of us would agree that this discrimination is better for the world since it is helping prevent the spread of coronavirus. But what about healthcare institutions like the one mentioned in my example above? Should private healthcare institutions be allowed to discriminate based upon coronavirus suspicion? While legally these institutions have the right to discriminate upon the basis of infectious disease, healthcare professionals have a much higher ethical obligation to the patient that overrides any legal or constitutional argument applicable.

There are two fields of thought to ponder in this argument over the right to discriminate over infectious disease. First, the legal and second, the ethical.

Legally a privately owned American business has the right to discriminate on the basis of infectious disease precaution. As stated above, I wholeheartedly agree with this right as it protects the community (if they choose to disallow those potentially exposed to or with coronavirus) and protects the sanctity of privately-owned business. Its when these private businesses are based around health care that I perceive a startling reality.

The Hippocratic Oath calls upon physicians to swear to uphold ethical standards in regard to their medical practices. This oath holds physicians to do what is good for the patientsand one could assume that this promotes anti-discriminatory practices. While not all medical students and doctors explicitly swear upon the same oath, we could extrapolate the premises of this oath to the plethora of others sworn by medical professionals every year.

When a doctor sees a patient in need, they should treat them as it is their ethical responsibility to do so. Today, many doctorsmostly in private practicesdeny patients out of fear of a coronavirus outbreak. While some may say this is out of caution and for the greater good, the physician denigrates the patient in favor of their own personal safety. Some may argue that the physician is protecting the community as well as themselves; however, if we start to care only for the greater good, we put the most helpless and feeble in danger.

When a healthcare worker enters into their field of work, they accept a formidable taskwhether literally or theoretically. Healthcare workers devote themselves to their patients and those in need. They help without discriminationespecially when its the most helpless. Why, then, do healthcare workers in private institutions neglect these standards when infectious disease is introduced? While I understand physicians are not contractually bonded to these standards, these standards are bound to their work. When physicians deny individualslike my fatherthey lose their perceived higher moral standing in society. These physicians that neglect the individual are no more of an upstanding citizen than the lay people as they care only for themselves when anxiety is high.

If we allow healthcare workers in privatized businesses to neglect their ethical obligations, we permit the societal abandonment of the most needy. We must remind healthcare workers of their obligations and their predecessor Hippocrates who would look down with shame at how these physicians and specialists are conducting their work. We must protect those discriminated against and ensure the care of allunhealthy or wellin these trying times of uncertainty and fear.

Read the original post:
Infectious Disease Discrimination and the Coronavirus - The Trinity Tripod

Childrens Health Defense

Special to Valley News

The law firm of Baum Hedlund Aristei & Goldman filed a lawsuit Wednesday, Sept. 16, against pharmaceutical giant Merck on behalf of a young man, Zachariah Otto, who was allegedly injured by Gardasil, Mercks HPV vaccine. The complaint seeks damages, including punitive damages, for negligence; strict liability or failure to warn; strict liability or manufacturing defect; breach of warranty; common law fraud and violation of Californias unfair competition law.

Otto claimed in the lawsuit that multiple Gardasil injections, which he first received at the age of 16, caused him to develop life-altering injuries, including dysautonomia, postural orthostatic tachycardia syndrome, orthostatic intolerance, small fiber neuropathy, chronic fatigue syndrome, mast cell activation syndrome, autoimmune disease and fibromyalgia, as well as a constellation of other serious health issues. POTS is an autoimmune condition that impacts the autonomic nervous system, which automatically regulates critical bodily functions, and the sympathetic nervous system, which is involved in the fight or flight response. POTS symptoms include fainting, migraine headaches and anxiety among many other serious conditions.

The plaintiff said the Gardasil-induced injuries have made him disabled to a point where he can no longer work and cannot physically attend college. His mother said it was Mercks intense Gardasil marketing campaign that encouraged her to have her son get the shots. Otto and his mother said that had they known of the serious risks associated with this vaccine, they would have never gone forward with the shots.

Merck fast-tracked Gardasil by presenting misleading data to the FDA and fabricating a health crisis, Ottos co-counsel Robert F. Kennedy, Jr. said. They claimed they were filling an unmet medical need but in reality, the only thing Merck was interested in filling was the $6 billion financial hole created by the Vioxx scandal.

Gardasil is racking up a long list of young women and men who were similarly harmed following vaccination with Mercks product. Childrens Health Defense has also been following the case of former athlete and scholar Jennifer Robi, who filed a lawsuit for Gardasil injuries against Merck in 2016. Robi is a 25-year-old woman who has been confined to a wheelchair since receiving her third Gardasil vaccine at age 16. Like Otto, she was diagnosed with POTS after receiving the series of Gardasil shots. Her attorneys alleged that Gardasils amorphous aluminum hydroxyphosphate sulfate adjuvant can over-stimulate the immune systems of vaccine recipients, tipping them into autoimmune conditions in which their redlining immune defenses begin attacking their bodies own organs. The autoimmune process allegedly caused a cascade of illnesses that, in Robis case, resulted in damage and deterioration in diverse organ systems throughout her body.

Colton Berrett, featured in the documentary film Vaxxed II, was another victim of Gardasil injury. Berrett was an active 13-year-old when he received the series of shots as advised by his physician before leaving for Boy Scouts camp in 2014. Two weeks after his third dose of Gardasil, Berrett experienced a sore neck followed by paralysis in his arms and hands. The paralysis continued to other parts of his body ultimately making Berrett completely paralyzed from the neck down and ventilator dependent through tracheostomy. Though he fought hard, he never recovered, and in January 2018, Berrett removed himself from the need of life support or the ventilator.

In this latest Gardasil lawsuit on behalf of Otto, Baum Hedlund accused Merck of knowingly and recklessly placing Gardasils profits ahead of patient safety. The team asked for punitive damages to deter Merck from withholding information on the serious adverse events associated with Gardasil while promoting it as safe and effective.

Most people think Gardasil is for girls, but since 2009, Merck has made billions in profit by marketing the HPV vaccine to the parents of boys and to young men, attorney Nicole K.H. Maldonado said. Through its advertising, Merck sold parents on the idea that Gardasil is a safe and effective tool to stop the spread of HPV and prevent cervical cancer. But Merck knew that Gardasil was neither safe nor effective at preventing cervical cancer, and worse, the company knew that Gardasil could cause a host of serious health issues.

Sign up for free news and updates from Robert F. Kennedy, Jr. and the Childrens Health Defense. CHD is implementing many strategies, including legal, in an effort to defend the health of our children and obtain justice for those already injured.

Here is the original post:
Lawsuit filed against Merck on behalf of young man allegedly injured by Gardasil - Valley News

Global Cardiac Autonomic Neuropathy Treatment Market Analysis

Persistence Market Research, in a recently published market study, offers valuable insights related to the overall dynamics of the Cardiac Autonomic Neuropathy Treatment market in the current scenario. Further, the report assesses the future prospects of the Cardiac Autonomic Neuropathy Treatment by analyzing the various market elements including the current trends, opportunities, restraints, and market drivers. The COVID-19 analysis section within the report offers timely insights regarding the impact of the global pandemic on the market. The presented study also offers data regarding the business and supply chain continuity strategies that are likely to assist stakeholders in the long-run.

As per the report, the Cardiac Autonomic Neuropathy Treatment market is set to grow at a CAGR of ~XX% over the forecast period (2019-2029) and exceed a value of ~US$ XX by the end of 2029. Some of the leading factors that are expected to drive the growth of the market include, focus towards research and development, innovations, and evolving consumer preferences among others.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/14518

Regional Outlook

The report scrutinizes the prospects of the Cardiac Autonomic Neuropathy Treatment market in different geographical regions. The scope of innovation, consumer behavior, and regulatory framework of each region is thoroughly analyzed in the presented study.

Distribution-Supply Channel Assessment

The report provides a thorough analysis of the different distribution channels adopted by market players in the global Cardiac Autonomic Neuropathy Treatment market along with the market attractiveness analysis of each distribution channel. The impact of the COVID-19 pandemic on the different distribution channels is enclosed in the report.

Product Adoption Analysis

key players in Cardiac autonomic neuropathy treatment market are Pfizer Inc., Roche Holding AG, Novartis, Amgen Inc., Privi Pharma Limited, Silverline Chemicals Limited, Anthem Biopharma, Praxis Pharmaceutical.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

The report covers exhaust analysis on:

The regional analysis includes:

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/14518

The report aims to address the following pressing questions related to the Cardiac Autonomic Neuropathy Treatment market:

Key Takeaways from the Cardiac Autonomic Neuropathy Treatment Market Report

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/14518

Why Companies Trust PMR?

See the original post here:
Cardiac Autonomic Neuropathy Treatment Market Is Expected To Experience An Impressive CAGR Growth Of XX% Through 2017 2025 - The Daily Chronicle

DEAR DR. ROACH: My father is 91 years old, and I am concerned that his elevated blood pressure isn't being properly addressed. Recently, it seems to run in the mid-170s to mid-80s (176/86). He has a number of health issues, such as a kidney stent every three months, diabetic neuropathy and a transient ischemic attack. He takes metoprolol (25 mg in the morning and evening). I sent a note to his doctor suggesting his blood pressure meds need to be reevaluated, and the doctor's response was to check his blood pressure several times daily for a month then let him know the average. He said the goal was an average blood pressure below 160/90 more than half the time.

I think a goal of 160 is too high and that four weeks is too long to wait before deciding if his meds need to be adjusted. I would like your opinion. -- L.F.

ANSWER: Your father's doctor may not want to use too many blood pressure medicines and cause symptoms that could affect your father's quality of life at age 91. On the other hand, a goal of 160/90 is not optimal, especially for someone who has already had a TIA (transient ischemic attack, which is often a predictor of a stroke). I think it's likely that your father could take medicines that control the blood pressure better but don't cause much if anything in terms of side effects.

A person with diabetes and high blood pressure, especially one who already has a complication like neuropathy, is at high risk for developing kidney disease from diabetes. ACE inhibitor drugs help reduce that risk as well as reduce the risk of heart attack, so I am very surprised he is not taking one. A beta blocker alone, like metoprolol, is not likely to be effective.

There remains some controversy about the ideal blood pressure goal for a person in your father's position. One recent study would suggest a goal of 120 is better than the older goal of less than 140. However, the blood pressure goal needs to be individualized. Side effects from blood pressure medications need to be carefully managed and may sometimes keep a person from reaching their goal. Still, blood pressure above 160 is not adequate control.

As far as timing, it's best to get as much data as possible before making a change in blood pressure medication. Four weeks is usually reasonable, but with your father's too-high blood pressure, two weeks should be enough time to confirm high blood pressures at home.

DEAR DR. ROACH: Do you think we will get sick from 5G towers? I have read that we will, but also that we won't. -- T.K.

ANSWER: Many studies have been done to look at health risks of radiation from cellphones and towers. After much research, there have been no health risks confirmed.

The main difference between 5G and previous cellphone radiation is the higher frequency of the electromagnetic radiation. Higher frequency may sound scary, but there is less penetration into the body than a lower frequency. This type of energy is non-ionizing and simply doesn't have the energy to damage DNA.

Readers may email questions to ToYourGoodHealth@med.cornell.edu. (c) 2020 North America Syndicate Inc.

Follow this link:
Roach: Optimal blood pressure goal needs to be individualized - LubbockOnline.com

This report additionally covers the effect of COVID-19 on the worldwide market. The pandemic brought about by Coronavirus (COVID-19) has influenced each part of life all inclusive, including the business segment. This has brought along a several changes in economic situations.

The Optic Neuropathy Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

It incorporates Optic Neuropathy Drug market evolution study, involving the current scenario, growth rate (CAGR), and SWOT analysis. Important the study on Optic Neuropathy Drug market takes a closer look at the top market performers and monitors the strategies that have enabled them to occupy a strong foothold in the market. Apart from this, the research brings to light real-time data about opportunities that will completely transform the trajectory of the business environment in the coming years to 2025. Some of the key players in the global Optic Neuropathy Drug market is cccc

Download Sample Copy of the Report to understand the structure of the complete report (Including Full TOC, Table & Figures) @ http://marketresearchbazaar.com/requestSample/29324

The global Optic Neuropathy Drug market size is estimated at xxx million USD with a CAGR xx% from 2015-2019 and is expected to reach xxx Million USD in 2020 with a CAGR xx% from 2020 to 2025. The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Optic Neuropathy Drug by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.

Product Type Coverage (Market Size Forecast, Major Company of Product Type etc.):

BA-240

IWP-953

LM-22A4

Others

Company Coverage (Company Profile, Sales Revenue, Price, Gross Margin, Main Products etc.):

Amgen Inc

BioAxone BioSciences Inc

Ironwood Pharmaceuticals Inc

Quark Pharmaceuticals Inc

Regenera Pharma Ltd

Regeneron Pharmaceuticals Inc

Application Coverage (Market Size Forecast, Different Demand Market by Region, Main Consumer Profile etc.):

Clinic

Hospital

Homecare

Region Coverage (Regional Production, Demand Forecast by Countries etc.):

North America (U.S., Canada, Mexico)

Europe (Germany, U.K., France, Italy, Russia, Spain etc.)

Asia-Pacific (China, India, Japan, Southeast Asia etc.)

South America (Brazil, Argentina etc.)

Middle East Africa (Saudi Arabia, South Africa etc.)

Enquiry Before Buying: http://marketresearchbazaar.com/enquiry/29324

Major Point of TOC:

Chapter One: Optic Neuropathy Drug Market Overview

Chapter Two: Optic Neuropathy Drug Market Segment Analysis by Player

Chapter Three: Optic Neuropathy Drug Market Segment Analysis by Type

Chapter Four: Optic Neuropathy Drug Market Segment Analysis by Application

Chapter Five: Optic Neuropathy Drug Market Segment Analysis by Sales Channel

Chapter Six: Optic Neuropathy Drug Market Segment Analysis by Region

Chapter Seven: Profile of Leading Optic Neuropathy Drug Players

Chapter Eight: Upstream and Downstream Analysis of Optic Neuropathy Drug

Chapter Nine: Development Trend of Optic Neuropathy Drug (2020-2029)

Chapter Ten: Appendix

Read Full Report: http://marketresearchbazaar.com/requestSample/global_optic_neuropathy_drug_market_analysis_2015-2019_and_forecast_2020-2025/detail/29324

If you have any special requirements, please let us know and we will offer you the report as you want.

About (Market Research Bazaar):

Market Research Bazaar (MRB)- a part of VRRB Reports LLP is an overall Market Research and consulting organization. We give unparalleled nature of offering to our clients present all around the world crosswise over industry verticals. Market Research Bazaar has aptitude in giving profound jump showcase understanding alongside advertise knowledge to our clients spread across over different endeavours.

Media Contact:

UK: +442070973908

US: +13156360953

India: +919548234540

Email:[emailprotected]

Website:http://marketresearchbazaar.com/

Blog:http://marketresearchbazaar.com/blogs

Follows to Twitter :https://twitter.com/BazaarMrb

Follows to Linkdin :https://www.linkedin.com/company/market-research-bazaar-vrrb/

Here is the original post:
Optic Neuropathy Drug Market Size Is Rising Tremendously Due To Increasing Need of Healthcare Services Centralization Till 2025 - The Daily Chronicle

DetailsCategory: AntibodiesPublished on Sunday, 20 September 2020 11:31Hits: 76

Trodelvy achieves a 27 percent overall response rate and a 5.9-month median duration of response in heavily-pretreated patients with metastatic urothelial cancer (mUC)

sBLA submission for accelerated approval expected in fourth quarter 2020, pending FDA final guidance

Phase 3 TROPiCS-04 study in third-line mUC underway

Company to host conference call and webcast today at 2:00 p.m. Eastern Time

MORRIS PLAINS, NJ, USA I September 19, 2020 I Immunomedics, Inc. (NASDAQ: IMMU) (Immunomedics or the Company), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced positive results from cohort 1 of cisplatin-eligible patients in the pivotal Phase 2 TROPHY U-01 study of Trodelvy (sacituzumab govitecan-hziy) in metastatic urothelial cancer (mUC). Results confirm the interim findings and prior Phase 1/2 study results showing Trodelvy has significant activity and is safe in patients with heavily-pretreated mUC who progressed on both platinum-based chemotherapy and checkpoint inhibitors (CPI).

Given that only about 10 percent of patients with mUC who have cancer progression after platinum-based and CPI therapy are expected to respond to single-agent chemotherapy with approximately two to three months of median progression-free survival, todays compelling results with sacituzumab govitecan offer patients and families new hope, commented Yohann Loriot, MD, PhD, Institut de Cancrologie Gustave Roussy, Villejuif, France, who gave the late-breaking oral presentation of the pivotal study at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

Results for cohort 1 of TROPHY U-01 are summarized in the table below. As of data cutoff on May 18, 2020, eight of the 31 responders have an ongoing response and remain on treatment. Trodelvy has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) in this indication.

* Based on blinded independent central assessment per RECIST v1.1

We believe that Trodelvy may offer a new treatment option for patients with mUC based on the successful data readout today, remarked Dr. Loretta M. Itri, Chief Medical Officer of Immunomedics. While we are seeking guidance from the FDA on the registrational pathway, the new Phase 3 TROPiCS-04 study in third-line mUC has been reviewed by FDA, is under review by the European Medicines Agency, and is currently in initiation phase.

Trodelvy continued to demonstrate a tolerable and predictable safety profile consistent with previous observations in mUC and other tumor types. Treatment-related Grade 3 and 4 adverse events were mostly hematologic and gastrointestinal related, including neutropenia (34%) and diarrhea (10%). Seven patients (6%) discontinued treatment due to adverse events, three of whom due to neutropenia or its complications. There was one treatment-related death from sepsis due to febrile neutropenia. There were no grade 2 or above events of neuropathy or rash, and no cases of interstitial lung disease reported.

About Immunomedics

Immunomedics is a leader in next-generation antibody-drug conjugate (ADC) technology, committed to help transform the lives of people with hard-to-treat cancers. Our proprietary ADC platform centers on using a novel linker that does not require an enzyme to release the payload to deliver an active drug inside the tumor cell and the tumor microenvironment, thereby producing a bystander effect. Trodelvy, our lead ADC, is the first ADC the FDA has approved for the treatment of people with metastatic triple-negative breast cancer and is also the first FDA-approved anti-Trop-2 ADC. For additional information on the Company, please visit its website at https://immunomedics.com/. The information on its website does not, however, form a part of this press release.

SOURCE: Immunomedics

Read more from the original source:
Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy in Metastatic Urothelial Cancer | Antibodies | News...

Stop the debilitating symptoms of neuropathy with help from Advanced Nerve and Health Center

HOUSTON Call Advanced Nerve and Health Center now at 832-626-1260 or log on to NerveAndHealth.com.

The Advanced Nerve and Health Center has a limited time offer for Great Day Houston viewers. For $29, get a tele-health visit, an in-office consultation, a copy of Dr. Thai's "Healthy Diet to Heal Nerve Pain" book, and a diagnostic nerve test to see if they can help. This is a $249 value.

Advanced Nerve and Health Center is located at 8558 Katy Freeway, Suite 116, Houston, TX 77024.

The Advanced Nerve and Health Center treats the root cause of neuropathy and reverses the damage to the nerve. Dr. Bao Thai and Dr. Aliena Sohail shared more in the video above about their process and how it works. Patient Anna Hernandez is extremely happy with the results. As a restaurant owner, she is on her feet all day long. The pain used to be so extreme, she couldn't walk a block without pain. After treatments, she's noticed significant change and is now able to walk longer distances. It has been life changing for her. She is very thankful for the nurturing and comforting nature of the staff at Advanced Nerve & Health Center.

This content sponsored by Advanced Nerve and Health Center.

Read more from the original source:
Live a life free of neuropathy - KHOU.com

Report Ocean recently published Diabetic Peripheral Neuropathy Treatment Market report which highlights the important factors that are expected to shape the growth of the Diabetic Peripheral Neuropathy Treatment Market over the forecast period. The current trends, market drivers, opportunities, and restraints are thoroughly evaluated to provide a clear understanding of the current market landscape of the Diabetic Peripheral Neuropathy Treatment Market. Technological innovation and advancement will further optimize the performance of the product, making it more widely used in downstream applications. Moreover, Porters Five Forces Analysis (potential entrants, suppliers, substitutes, buyers, industry competitors) provides crucial information for knowing the Diabetic Peripheral Neuropathy Treatment Market.

The COVID-19 (Coronavirus) outbreak has led to both advantages and disadvantages for companies in the Diabetic Peripheral Neuropathy Treatment Market. With the help of our recently published report, market players can adopt innovative strategies to overcome the challenges that lie ahead of the COVID-19 lockdown period. Through our research study, companies can gain factual information about COVID-19 and how its impacting the sales of products in the global market landscape.

Request Free Sample Report athttps://reportocean.com/industry-verticals/sample-request?report_id=mai50223

The report covers exhaustive analysis on:

Market Segments

Market Dynamics

Market Size

Supply & Demand

Current Trends/Issues/Challenges

Competition & Companies involved

Technology

Value Chain

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain in the Diabetic Peripheral Neuropathy Treatment Market. The report Diabetic Peripheral Neuropathy Treatment Market provide in-depth analysis of current market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on Diabetic Peripheral Neuropathy Treatment Market segments and geographies.

This Diabetic Peripheral Neuropathy Treatment Market report begins with a basic overview of the market. The analysis highlights the opportunity and Diabetic Peripheral Neuropathy Treatment Market trends that are impacted the market. Players around various regions and analysis of each industry dimensions are covered under this report. The analysis also contains a crucial Diabetic Peripheral Neuropathy Treatment Market insight regarding the things which are driving and affecting the earnings of the market.

The Report offers SWOT examination and venture return investigation, and other aspects such as the principle locale, economic situations with benefit, generation, request, limit, supply, and market development rate and figure.

Quantifiable data:-

Market Data Breakdown by Key Geography, Type & Application / End-User

By type (past and forecast)

Diabetic Peripheral Neuropathy Treatment Market: Specific Applications Sales and Growth Rates (Historical & Forecast)

Diabetic Peripheral Neuropathy Treatment Market revenue and growth rate by the market (history and forecast)

Diabetic Peripheral Neuropathy Treatment Market size and growth rate, application and type (past and forecast)

Competitive Landscape:Key players in the global Diabetic Peripheral Neuropathy Treatment market covered in Chapter 4:Reata Pharmaceuticals IncKPI Therapeutics IncAchelios Therapeutics IncViroMed Co LtdNovaremed LtdCommence Bio IncGrunenthal GmbHImmune Pharmaceuticals IncMitsubishi Tanabe Pharma CorpMedifron DBT Co LtdRelief Therapeutics Holding AGDiabetic Peripheral Neuropathy Treatment Market competitive landscape provides details and data information by major players. Details included are company description, major business, company total revenue and the sales, revenue generated in Diabetic Peripheral Neuropathy Treatment Market business, the date to enter into the Diabetic Peripheral Neuropathy Treatment Market, product introduction, recent developments, etc.

Market Segmentation:

The segmentation is used to decide the target market into smaller sections or segments like product type, application, and geographical regions to optimize marketing strategies, advertising technique and global as well as regional sales efforts of Diabetic Peripheral Neuropathy Treatment Market.

Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering North America, Europe, China, Japan, Southeast Asia, India, Middle East and Africa and Central and South America.

Study objectives of Diabetic Peripheral Neuropathy Treatment Market Report:

To provide economic factors, technology trends, and market trends that influence the global Diabetic Peripheral Neuropathy Treatment Market growth

To provide historical, current, and forecast revenue of market segments and sub-segments with respect to regional markets and key countries

To provide historical, current, and forecast revenue of market segments based on material, type, design, and end-user

To provide a detailed analysis of the market structure along with the forecast of various segments and sub-segments of the global Diabetic Peripheral Neuropathy Treatment Market

To provide strategic profiling of key players in the market, comprehensively analyzing their market shares, core competencies, and drawing a competitive landscape for the market

Inquire or Share Your Questions If Any before Purchasing This Report:https://reportocean.com/industry-verticals/sample-request?report_id=mai50223

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe, and Asia.

Contact Us: +1 888 212 3539 (US) +91-9997112116 (Outside US)Contact Person: Matthew SEmail:[emailprotected]

See more here:
Comprehensive Report on Diabetic Peripheral Neuropathy Treatment Market by global COVID-19 impact analysis, industry trends, business strategies,...

Market Size US$ 10,414.0 Mnin 2024, Market Growth CAGR of 5.6%, Market Trends Growing prevalence ofHealthcare Industry

Reaching the revenues of over US$ 6 Bn at the end of 2019, the globalneuropathic pain management marketis projected for a healthy CAGR during the forecast period (2019 2029). Increasing prevalence of neuropathic pain disorders and growing awareness about pain medication are boosting the demand for pain management drugs.

Pipeline strategies by manufacturers are focused on introducing advanced drugs with minimum side effects to increase market share. For instance, Pfizer sponsored drug Pregabalin, effective in treating neuropathic (nerve) pain resulting from peripheral nerve trauma that is in phase 3 clinical trials. Increasing research and development activities to develop medications for indications such as post-herpetic neuralgia are creating significant opportunities for manufactures to flourish in the market.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/4149

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/4149

Key Takeaways Neuropathic Pain Management Market Study

Increasing prevalence of diabetic neuropathy and availability of approved neuropathy pain medications have significantly added to the opportunities for market growth, thereby fostering the rate of adoption of neuropathic pain management drugs.

Increasing R&D Spending by Pharmaceuticals Companies Shaping Future

One of the key factors observed to impact the neuropathic pain management market growth is the development of new drugs for treatment of neuropathic and chronic pains. Companies are focusing on clinical trials to develop drugs for efficient treatment of neuropathic pain. For instance, Eli Lilly and Company developed Duloxetine (LY248686) for Diabetic Peripheral Neuropathic Pain (DPNP) that is under phase 4 clinical trial.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/4149

At the same time, companies are focused on expanding therapeutic applications of drugs such as opioids and steroids for neuropathic pain management without causing any serious side effects to patients. Currently, more than 100 clinical trials are been carried out for pain management. Among those clinical trials, nearly half of the clinical trials are for various indications of neuropathic pain such as diabetic neuropathy and post-herpetic neuralgia.

What Does the Report Cover?

The neuropathic pain management market, a new study from Persistence Market Research, provides unparalleled insights on evolution of the neuropathic pain management market during 2014 2018 and presents demand projections during 2019 2029 on the basis of drug class (tricyclic anti-depressants, anticonvulsants, SNRIs, capsaicin cream, local anesthesia, opioids, steroids, and others), indication (diabetic neuropathy, trigeminal neuralgia, post-herpetic neuralgia, chemotherapy-induced peripheral neuropathy and others), distribution channel (retail pharmacies, hospital pharmacies, and online pharmacies) across prominent regions (North America, Latin America, Europe, Asia Pacific and MEA).

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish KoltePersistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Website https://www.persistencemarketresearch.com

Follow this link:
Sales Of To Compel The Neuropathic Pain Market To Reach In 2024 - Scientect

The combination of the ixazomib, dexamethasone, and rituximab (IDR) yields durable responses and maintains an excellent safety profile in patients with Waldenstrm macroglobulinemia (WM), according to results of a study published in Blood Advances.

The investigators elected to assess IDR due to the favorable safety profile of ixazomib, in particular a low incidence of neuropathy, in multiple myeloma.

The long-term follow-up results included all 26 treatment-naive patients with WM who participated in the prospective, phase 2 clinical trial (ClinicalTrials.gov Identifier: NCT02400437) that evaluated the combination of IDR.

For the study, IDR was administered over 12 cycles: six 4-week induction cycles followed by six 8-week maintenance cycles.

All patients had the MYD88 L265P mutation, and CXCR4 mutations were present in 15 patients (58%). The median age at treatment initiation was 65 years (range, 46-82 years).

The median time to response was 2 months, and the median time to major response was 6 months. CXCR4 mutation status appeared to have an effect on the time to response; patients with CXCR4 mutations had a longer median time to response than those without mutations (3 months vs 1 month, respectively; P =.003). However, no significant difference was observed in the median time to major response between the genotypes (10 months vs 3 months, respectively; P =.31).

IDR induced high rates of response among the cohort. The overall response rate was 96% (95% CI, 80-100) while the major response rate was 77% (95% CI, 56-91). At best response, 19% of patients achieved a very good partial response (VGPR), 58% achieved a partial response, 19% had a minor response, and 4% had stable disease. The rate of VGPR was higher in patients without CXCR4 mutations than in patients with CXCR4 mutations (36% vs 7%; P =.06).

Among all patients, the median progression-free survival and median duration of response (DOR) was 40 months and 38 months, respectively. The median time to next treatment was also 40 months. None of these outcomes were associated with CXCR4 mutational status.

The safety profile was considered excellent, although some patients experienced grade 3 adverse events, which included infections (2 patients, unrelated to treatment), hyperglycemia (2 patients, from dexamethasone), infusion reactions (2 patients, with rituximab), and neuropathy (1 patients, due to uncontrolled diabetes). No grade 4 adverse events or deaths occurred.

The authors concluded, On the basis of the findings of our study, IDR represents an easy-to-administer, safe, and effective treatment option for patients with WM, with high rates of durable responses and an excellent adverse event profile.

Disclosures: Some authors have declared affiliations with or received funding from the pharmaceutical industry. Please refer to the original study for a full list of disclosures.

Castillo JJ, Meid K, Flynn CA, et al. Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenstrm macroglobulinemia: long-term follow-up. Blood Adv. 2020;4(16):3952-3959. doi:10.1182/bloodadvances.2020001963

Continue reading here:
Waldenstrm Macroglobulinemia Treated With Ixazomib Combination Therapy: Long-Term Follow Up - Hematology Advisor

In this report, the global Chemotherapy Induced Peripheral Neuropathy market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025.

Persistence Market Research recently published a market study that sheds light on the growth prospects of the global Chemotherapy Induced Peripheral Neuropathy market during the forecast period (20XX-20XX). In addition, the report also includes a detailed analysis of the impact of the novel COVID-19 pandemic on the future prospects of the Chemotherapy Induced Peripheral Neuropathy market. The report provides a thorough evaluation of the latest trends, market drivers, opportunities, and challenges within the global Chemotherapy Induced Peripheral Neuropathy market to assist our clients arrive at beneficial business decisions.

The Chemotherapy Induced Peripheral Neuropathy market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the Chemotherapy Induced Peripheral Neuropathy market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/30209

Resourceful insights enclosed in the report:

The major players profiled in this Chemotherapy Induced Peripheral Neuropathy market report include:

key players and product offerings

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/30209

The market report addresses the following queries related to the Chemotherapy Induced Peripheral Neuropathy market:

The study objectives of Chemotherapy Induced Peripheral Neuropathy Market Report are:

To analyze and research the Chemotherapy Induced Peripheral Neuropathy market status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.

To present the Chemotherapy Induced Peripheral Neuropathy manufacturers, presenting the sales, revenue, market share, and recent development for key players.

To split the breakdown data by regions, type, companies and applications

To analyze the global and key regions Chemotherapy Induced Peripheral Neuropathy market potential and advantage, opportunity and challenge, restraints and risks.

To identify significant trends, drivers, influence factors in global and regions

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the Chemotherapy Induced Peripheral Neuropathy market.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/30209

Read more:
Chemotherapy Induced Peripheral Neuropathy Market Set To Register A CAGR Growth Of XX% Over The Forecast Period 2019 2029 - Daily Research Chronicle

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the neuropathy pain treatment market and it is poised to grow by USD 1.70 billion during 2020-2024, progressing at a CAGR of almost 5% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities. Technavios in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis. Download a Free Sample Report on COVID-19 Impacts

Frequently Asked Questions-

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Abbott Laboratories, Assertio Therapeutics Inc., AstraZeneca Plc, Baxter International Inc., Eli Lilly and Co., Endo International Plc, Johnson & Johnson, Pfizer Inc., and Sanofi are some of the major market participants. The presence of large patient pool will offer immense growth opportunities. To make most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations.

Neuropathy Pain Treatment Market 2020-2024: Segmentation

Neuropathy Pain Treatment Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43322

Neuropathy Pain Treatment Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The neuropathy pain treatment market report covers the following areas:

This study identifies growing focus on the development of drugs for the treatment of diabetic neuropathy pain as one of the prime reasons driving the neuropathy pain treatment market growth during the next few years.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform

Neuropathy Pain Treatment Market 2020-2024: Key Highlights

Table of Contents:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Indication

Market Segmentation by drug class

Customer landscape

Geographic Landscape

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Visit link:
Neuropathy Pain Treatment Market Analysis Highlights the Impact of COVID-19 (2020-2024) |Presence of Large Patient Pool to boost the Market Growth |...

The pathophysiology of pain in neuropathy is complex and may be linked to sensory phenotypes. Quantitative sensory testing, a standardized method to evaluate sensory profiles in response to defined stimuli, assesses functional integrity of small and large nerve fiber afferents and central somatosensory pathways. It has revealed detailed insights into mechanisms of neuropathy, yet, it remains unclear if pain directly affects sensory profiles. The main objective of this study was to investigate sensory profiles in patients with various neuropathic conditions, including polyneuropathy, mononeuropathy, and lesions to the central nervous system, in relation to self-reported presence or absence of pain and pain sensitivity using the Pain Sensitivity Questionnaire.A total of 443 patients (332 painful and 111 painless) and 112 healthy participants were investigated. Overall, loss of sensation was equally prevalent in patients with and without spontaneous pain. Pain thresholds were equally lowered in both patient groups, demonstrating that hyperalgesia and allodynia is just as present in patients not reporting any pain. Remarkably, this was similar for dynamic mechanical allodynia. Hypoalgesia was more pronounced in painful polyneuropathy whereas hyperalgesia was more frequent in painful mononeuropathy (compared to painless conditions). Self-reported pain sensitivity was significantly higher in painful than in painless neuropathic conditions.Our results reveal the presence of hyperalgesia and allodynia in patients with central and peripheral lesions of the somatosensory system not reporting spontaneous pain. This shows that symptoms and signs of hypersensitivity may not necessarily coincide, and that painful and painless neuropathic conditions may mechanistically blend into one another.

PubMed

View post:
No pain, still gain (of function): the relation between sensory profiles and the presence or absence of self-reported pain in a large multicenter...

More than half of women who underwent treatment for breast cancer experienced physical/functional complications involving an upper limb, according to results of a cross-sectional study published in Supportive Care in Cancer.1

Although a high incidence of posttreatment upper limb dysfunction has been previously reported in survivors of breast cancer, the aim of this study was to take a closer look at the underlying causes of this condition in women with a history of breast cancer.

Knowing what actually influences the development of upper limb dysfunction after breast cancer treatment can help healthcare professionals minimize the incidence of this complication, thus reducing the physical and functional impact of the disease and providing a better quality of life of survivors, the study authors commented.

This study involved adult women who had received breast cancer treatment between 2009 and 2016 at 1 of 2 institutions in Brazil.

Data related to sociodemographic characteristics and treatment history were collected during a patient interview and/or review of the patient medical record. The Disabilities of Arm, Shoulder and Hand (DASH) questionnaire was used to assess the impact of breast cancer treatment on the upper limb.2

Regarding the selection of the DASH questionnaire, the study authors explained that most of the instruments used to assess complications include physical examination with measurement of range of motion, muscle strength, and sensory capacity, and because they are limited to physical issues, many are unable to identify the level of independence and functionality for performing daily life activities related to the upper limbs.

They further clarified that the incorporation of patient-reported outcome measures into the DASH questionnaire also allowed for assessment of patient quality of life.

Other patient assessments included evaluations for the presence of lymphedema in the upper limb, breast skin sensitivity, paresthesia, pain, and scar adherence.

Of the 233 women included in this study, the mean patient age was 56.3 years. All patients underwent surgery for breast cancer with an average of approximately 5 years between surgical treatment and assessment. Lymphadenectomy was performed in 60.2% of patients, with the remaining patients having undergone either sentinel lymph node dissection or no surgical assessment of the lymph nodes. Approximately three-quarters of patients had received chemotherapy, radiation therapy, and were overweight/obese based on body mass index (BMI).

Key study findings included some level of upper limb dysfunction and evidence for sensory intercostobrachial nerve damage in 55.4% and 47.2% of patients, respectively.

Of note, analyses based on models adjusted for age and BMI showed that only paresthesia due to intercostobrachial nerve damage was significantly associated with upper limb dysfunction in these patients (odds ratio [OR], 1.96; 95% CI, 1.06-3.60; P =.03).

In summarizing the findings from this study, the study authors stated that upper limb dysfunction is a frequent complication after breast cancer treatment and may be associated with neuropathies due to changes in the intercostobrachial nerve pathway.

Reference

1. Siqueria TC, Fragoas SP, Pelegrini A, de Oliveira AR, Medeiros da Luz C. Factors associated with upper limb dysfunction in breast cancer survivors. Support Care Cancer. Published online August 17, 2020. doi:10.1007/s00520-020-05668-7

2. Beaton DE, Katz JN, Fossel AH, Wright JG, Tarasuk V, Bombardier C. Measuring the whole or the parts? Validity, reliability, and responsiveness of the Disabilities of the Arm, Shoulder and Hand outcome measure in different regions of the upper extremity. J Hand Ther. 2001;14(2):128-146.

Visit link:
Neuropathy May Be Primary Cause of Upper Limb Dysfunction in Breast Cancer Survivors, Study Finds - Oncology Nurse Advisor

Diabetic neuropathy refers to the nerve damage caused due to diabetes. Diabetic neuropathy most often damages nerves in the legs and feet. However, it can injure nerve fibers throughout the body. Diabetic neuropathy is a common complication of both type 1 and type 2 diabetes. Increasing diabetic population and growing awareness among people about diabetes and related complications are some of the major factors that drive the diabetic neuropathy market. Types of diabetic neuropathy include peripheral neuropathy, autonomic neuropathy, proximal neuropathy, focal neuropathy, and other diabetic nerve damage. The peripheral diabetic neuropathy affects the feet and legs. It causes loss of sensation, and sometimes pain in the feet, legs, and hands. Autonomic diabetic neuropathy affects body functions such as heart rate, blood pressure, perspiration, and digestion. Proximal diabetic neuropathy affects thighs, hips, buttocks, and legs. Focal diabetic neuropathy affects the nerves, most often in the wrist, thigh, or foot. In addition, it also affects the nerves of the back, chest, and the nerves that control the eye muscles. Some of the factors that cause nerve damage in diabetes condition includes poor blood sugar control, kidney disease, smoking, excess weight, and length of time to have diabetes. However, anyone who has diabetes can develop neuropathy. Some symptoms of diabetic neuropathy are pain, tingling, numbness, and loss of feeling in the hands, arms, feet, and legs. The treatment options for diabetic neuropathy include drugs, radiotherapy, and physiotherapy.

To remain ahead of your competitors, request for a sample [emailprotected]

https://www.persistencemarketresearch.com/samples/4795

The global diabetic neuropathy market is categorized based on medication, radiotherapy, and physiotherapy. Based on medication, the report covers antispasmodic, antidepressant, and others. Based on radiotherapy, the market comprises transcutaneous electrical nerve stimulation (TENS).

North America has the largest market for diabetic neuropathy, followed by Europe. This is due to the increasing number of patients with diabetes, rise in research and development activities, increasing awareness among people about diabetes and related complications, and improved healthcare infrastructure in the region. The diabetic neuropathy market in Asia is expected to experience high growth rate in the next few years. This is due to rising R&D activities for drug discovery and development, increasing government supports in the form of funding, growing awareness about diabetic neuropathy, and developing healthcare infrastructure in the region. In addition, growing demographics and economies in the developing countries such as India, China, and Japan are expected to lead growth in the diabetic neuropathy market in Asia.

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/4795

Increasing prevalence of diabetes cases, growing, aging population, rise in healthcare expenditure for diabetes, growing awareness about diabetes and related nerve complications, and rise in R&D activities in drug discovery and developmemt are the key factors driving the global diabetic neuropathy market. However, high failure rate in clinical trials, stringent regulatory requirements, and longer approval time for drugs are some of the factors restraining the growth for global diabetic neuropathy market.

Increasing number of mergers and acquisitions, rapid product launches, and rise in number of collaborations and partnerships are some of the latest trends that have been observed in the global diabetic neuropathy market.

You Can Request for TOC Here @ https://www.persistencemarketresearch.com/toc/4795

Explore Extensive Coverage of PMR`s

Life Sciences & Transformational HealthLandscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor, New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

Go here to read the rest:
Demand for Diabetic Neuropathy Market to Witness Rapid Surge During the Period 2015 2021 - thedailychronicle.in

In 2029, the Neuropathy Pain Treatment market is spectated to surpass ~US$ xx Mn/Bn with a CAGR of xx% over the forecast period. The Neuropathy Pain Treatment market clicked a value of ~US$ xx Mn/Bn in 2018. Region is expected to account for a significant market share, where the Neuropathy Pain Treatment market size is projected to inflate with a CAGR of xx% during the forecast period.

In the Neuropathy Pain Treatment market research study, 2018 is considered as the base year, and 2019-2029 is considered as the forecast period to predict the market size. Important regions emphasized in the report include region 1 (country 1, country2), region 2 (country 1, country2), and region 3 (country 1, country2).

Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2641417&source=atm

Global Neuropathy Pain Treatment market report on the basis of market players

The report examines each Neuropathy Pain Treatment market player according to its market share, production footprint, and growth rate. SWOT analysis of the players (strengths, weaknesses, opportunities and threats) has been covered in this report. Further, the Neuropathy Pain Treatment market study depicts the recent launches, agreements, R&D projects, and business strategies of the market players including

Competition AnalysisIn the competitive analysis section of the report, leading as well as prominent players of the global Neuropathy Pain Treatment market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Neuropathy Pain Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Neuropathy Pain Treatment market.The following players are covered in this report:PfizerDepomedEli LillyEndoGrnenthal GroupArbor PharmaceuticalsNeuropathy Pain Treatment Breakdown Data by TypeCalcium Channel Alpha 2-delta LigandsSerotonin-norepinephrine Reuptake InhibitorsOthersNeuropathy Pain Treatment Breakdown Data by ApplicationRetail PharmaciesHospitalsOthers

Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2641417&source=atm

The Neuropathy Pain Treatment market report answers the following queries:

The Neuropathy Pain Treatment market report provides the below-mentioned information:

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2641417&licType=S&source=atm

Research Methodology of Neuropathy Pain Treatment Market Report

The global Neuropathy Pain Treatment market study covers the estimation size of the market both in terms of value (Mn/Bn USD) and volume (x units). Both top-down and bottom-up approaches have been used to calculate and authenticate the market size of the Neuropathy Pain Treatment market, and predict the scenario of various sub-markets in the overall market. Primary and secondary research has been thoroughly performed to analyze the prominent players and their market share in the Neuropathy Pain Treatment market. Further, all the numbers, segmentation, and shares have been gathered using authentic primary and secondary sources.

Read the original here:
Neuropathy Pain Treatment Market 10-Year Market Forecast and Trends Analysis Research Report - Scientect

The research report on Peripheral Neuropathy Treatment market Size provides a thorough assessment of this business vertical. As per the study, the market is predicted to accumulate significant revenues and showcase a substantial growth rate during the estimated timeframe.

The Peripheral Neuropathy Treatment market report is a thorough investigation of the industry in terms of consumption and production. The report, based on the production facet, encompasses details regarding the manufacturing structure and profit margins of the renowned manufacturers. The price incurred by the companies to produce, store, and sell one unit of a product across the various geographies over the analysis period are also included in the study.

Speaking of the consumption aspect, the study details the consumption value and consumption volume of the products in question. Data pertaining to the individual sales price along with the import and export patterns spanning various territories are delivered in the report. Additionally, the report also predicts the production and consumption patterns over the assessment period.

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/185890

Key pointers from the competitive landscape:

An outline of the regional landscape:

A brief overview of the product spectrum:

A summary of the application terrain:

In conclusion, the report evaluates the Peripheral Neuropathy Treatment market through multiple classifications and provides thorough information about the upstream raw materials, downstream buyers, and distribution channels established by the various competitors. More importantly, a study of recent market trends, drivers, challenges, and opportunities shaping the profitability graph of the industry are duly presented in the report.

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/185890

Continued here:
Peripheral Neuropathy Treatment Market Worldwide Industry Share, Size, Gross Margin, Trend, Future Demand and Forecast till 2025 - Express Journal

The latest report on 2020-2029 Report on Global Neuropathy Pain Treatment Market by Player, Region, Type, Application and Sales Channel gives a broad assessment of the global Neuropathy Pain Treatment market by categorizing it in terms applications, types, and regions. The report gives a detailed analysis on competitive landscape and strategies that influenced the market in a positive way. Further, the report gives an overview of current market dynamics by studying various key segments based on the product, types, applications, end-to-end industries and market scenario.

Major Key Playersof Neuropathy Pain Treatment Market Report:Pfizer, Depomed, Eli Lilly, Endo, Grnenthal Group, Arbor Pharmaceuticals

Request a sample of this report @ https://www.regalintelligence.com/request-sample/159875

Market split by Type, can be divided into:

Calcium Channel Alpha 2-Delta Ligands

Serotonin-Norepinephrine Reuptake Inhibitors

Others

Market split by Application, can be divided into:

Retail Pharmacies

Hospitals

Others

Market split by Sales Channel, can be divided into:

Direct Channel

Distribution Channel

Market segment by Region/Country including:

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia and Spain etc.)

Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.)

South America (Brazil, Argentina and Colombia etc.)

Middle East & Africa (South Africa, UAE and Saudi Arabia etc.)

Reach us to quote the effective price of this report @https://www.regalintelligence.com/check-discount/159875

Table of Contents

Chapter 1 Neuropathy Pain Treatment Market Overview

1.1 Neuropathy Pain Treatment Definition

1.2 Global Neuropathy Pain Treatment Market Size Status and Outlook (2014-2029)

1.3 Global Neuropathy Pain Treatment Market Size Comparison by Region (2014-2029)

1.4 Global Neuropathy Pain Treatment Market Size Comparison by Type (2014-2029)

1.5 Global Neuropathy Pain Treatment Market Size Comparison by Application (2014-2029)

1.6 Global Neuropathy Pain Treatment Market Size Comparison by Sales Channel (2014-2029)

1.7 Neuropathy Pain Treatment Market Dynamics (COVID-19 Impacts)

1.7.1 Market Drivers/Opportunities

1.7.2 Market Challenges/Risks

1.7.3 Market News (Mergers/Acquisitions/Expansion)

1.7.4 COVID-19 Impacts on Current Market

1.7.5 Post-Strategies of COVID-19 Outbreak

Chapter 2 Neuropathy Pain Treatment Market Segment Analysis by Player

2.1 Global Neuropathy Pain Treatment Sales and Market Share by Player (2017-2019)

2.2 Global Neuropathy Pain Treatment Revenue and Market Share by Player (2017-2019)

2.3 Global Neuropathy Pain Treatment Average Price by Player (2017-2019)

2.4 Players Competition Situation & Trends

2.5 Conclusion of Segment by Player

Chapter 3 Neuropathy Pain Treatment Market Segment Analysis by Type

3.1 Global Neuropathy Pain Treatment Market by Type

3.1.1 Calcium Channel Alpha 2-Delta Ligands

3.1.2 Serotonin-Norepinephrine Reuptake Inhibitors

3.1.3 Others

3.2 Global Neuropathy Pain Treatment Sales and Market Share by Type (2014-2019)

3.3 Global Neuropathy Pain Treatment Revenue and Market Share by Type (2014-2019)

3.4 Global Neuropathy Pain Treatment Average Price by Type (2014-2019)

3.5 Leading Players of Neuropathy Pain Treatment by Type in 2019

3.6 Conclusion of Segment by Type

Chapter 4 Neuropathy Pain Treatment Market Segment Analysis by Application

4.1 Global Neuropathy Pain Treatment Market by Application

4.1.1 Retail Pharmacies

4.1.2 Hospitals

4.1.3 Others

4.2 Global Neuropathy Pain Treatment Sales and Market Share by Application (2014-2019)

4.3 Leading Consumers of Neuropathy Pain Treatment by Application in 2019

4.4 Conclusion of Segment by Application

Chapter 5 Neuropathy Pain Treatment Market Segment Analysis by Sales Channel

5.1 Global Neuropathy Pain Treatment Market by Sales Channel

5.1.1 Direct Channel

5.1.2 Distribution Channel

5.2 Global Neuropathy Pain Treatment Sales and Market Share by Sales Channel (2014-2019)

5.3 Leading Distributors/Dealers of Neuropathy Pain Treatment by Sales Channel in 2019

5.4 Conclusion of Segment by Sales Channel

Chapter 6 Neuropathy Pain Treatment Market Segment Analysis by Region

6.1 Global Neuropathy Pain Treatment Market Size and CAGR by Region (2014-2029)

6.2 Global Neuropathy Pain Treatment Sales and Market Share by Region (2014-2019)

6.3 Global Neuropathy Pain Treatment Revenue and Market Share by Region (2014-2019)

6.4 North America

6.4.1 North America Market by Country

6.4.2 North America Neuropathy Pain Treatment Market Share by Type

6.4.3 North America Neuropathy Pain Treatment Market Share by Application

6.4.4 United States

6.4.5 Canada

6.4.6 Mexico

6.5 Europe

6.5.1 Europe Market by Country

6.5.2 Europe Neuropathy Pain Treatment Market Share by Type

6.5.3 Europe Neuropathy Pain Treatment Market Share by Application

6.5.4 Germany

6.5.5 UK

6.5.6 France

6.5.7 Italy

6.5.8 Russia

6.5.9 Spain

6.6 Asia-Pacific

6.6.1 Asia-Pacific Market by Country

6.6.2 Asia-Pacific Neuropathy Pain Treatment Market Share by Type

6.6.3 Asia-Pacific Neuropathy Pain Treatment Market Share by Application

6.6.4 China

6.6.5 Japan

6.6.6 Korea

6.6.7 India

6.6.8 Southeast Asia

6.6.9 Australia

6.7 South America

6.7.1 South America Market by Country

6.7.2 South America Neuropathy Pain Treatment Market Share by Type

Excerpt from:
Post-pandemic Analysis on Neuropathy Pain Treatment Market Likely to Emerge Over A Period Of 2020 2029 - Galus Australis